Product Description
Mechanisms of Action: DNA Damager
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Institut Cancerologie de l'Ouest
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Adenocarcinoma|Hypoxia|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT00574353 | N/A |
Completed |
Colorectal Cancer|Hypoxia |
2024-07-05 |
2025-05-10 |
Patient Enrollment|Primary Endpoints|Treatments |
|
| HYPOXProstat | P2 |
Completed |
Prostate Cancer|Hypoxia|Adenocarcinoma |
2014-11-01 |
2019-03-19 |
Treatments |